Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Empower Clinics Inc (OP: EPWCF )

N/A UNCHANGED
Last Price Updated: 9:50 AM EDT, Oct 11, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Empower Clinics Inc

< Previous 1 2 3 4 5 Next >
Empower Clinics Provides Corporate Update
Via ACCESSWIRE
Empower Clinics Announces Closing of Second Tranche Private Placement Financing
Via ACCESSWIRE
The Power Play by The Market Herald Releases New Interviews with Beyond Oil, Empower Clinics and Nextech3D.ai Discussing Their Latest News
Via ACCESSWIRE
Empower Clinics Announces Closing of First Tranche Private Placement Financing
Via ACCESSWIRE
Empower Clinics Announces Proposal For Division Spin Out
Via ACCESSWIRE
Empower Clinics Provides Corporate Update
Via ACCESSWIRE
Empower Clinics Provides Corporate Update
Via ACCESSWIRE
CORRECTION: Empower Clinics Reports Q4 2022 Results
Via ACCESSWIRE
Empower Clinics Signs New Agreements To Advance Growth Of Research and Clinical Trials with Signing Of Two Additional Principal Investigators - And Are Approved To Process Multiple Clinical Study Applications From Pharmaceutical Sponsors
Via ACCESSWIRE
Empower Clinics Announces Proposed Private Placement
Via ACCESSWIRE
Empower Clinics Announces Share Consolidation
Via ACCESSWIRE
Empower Clinics Signs Letter of Intent for $5 Million Equity Capital Facility and Provides Additional Corporate Updates
Via ACCESSWIRE
Empower Clinics Advances Research and Clinical Trials Division with The Signing of Another Experienced Principal Investigator
Via ACCESSWIRE
Empower Clinics Reports Q4 2022 Results
Via ACCESSWIRE
Empower Clinics Announces $2 Million CAD Offering of Common Shares and Common Share Purchase Warrants
Via ACCESSWIRE
Empower Clinics to Consolidate Operations at The Medi-Collective
Via ACCESSWIRE
Empower Clinics Accelerates Growth of Research and Clinical Trials Division with Signing of Two Additional Principal Investigators at First Site in Dallas, Texas
Via ACCESSWIRE
Empower Clinics Announces Official Launch of Mobile Technology & Communications Platform, PulseIR Powered by Fobi
Via ACCESSWIRE
Empower Clinics Signs Agreement To Conduct Research and Clinical Trials with Dallas, TX Based Medical Center - And Major Milestone With Signing Of Research Services Agreement With First Principal Investigator
Via ACCESSWIRE
Empower Clinics Announces Exploration of Strategic Alternatives
Via ACCESSWIRE
Empower Clinics Cancels Previously Announced Private Placement
Via ACCESSWIRE
Empower Clinics Subsidiary Wins Laboratory Services Agreement with European Medical Products Manufacturer
Via ACCESSWIRE
Empower Clinics Advances Partnership to Launch US Clinical Trial Management Services with Formation of Delaware Based Company and Identification of Principal Investigators
Via ACCESSWIRE
CORRECTION: Empower Clinics Announces FOBI Partnership To Elevate Investor Relations With Digital, Mobile and Personalized Engagement
Via ACCESSWIRE
Empower Clinics Signs Letter of Intent for Partnership to Launch US Clinical Trial Management Services for Biotech and Pharmaceutical Industries
Via ACCESSWIRE
Empower Clinics Announces FOBI Partnership to Elevate Investor Relations with Digital, Mobile and Personalized Engagement
Via ACCESSWIRE
Empower Clinics Subsidiary Receives Approvals for Government Reimbursement From Four Government Administrations
Via ACCESSWIRE
Empower Clinics Subsidiary Signs Laboratory Services Agreement with US Healthcare Provider for Underserved Americans
Via ACCESSWIRE
Empower Clinics Announces New Auditor and Change of Year End
Via ACCESSWIRE
Empower Clinics Signs Partnership Agreement with Leading European Medical Diagnostics and Device Company
Via ACCESSWIRE
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.